Exact Sciences, Pfizer enter into promotion agreement for Cologuard

Exact Sciences (EXAS) and Pfizer (PFE) announced an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer will join Exact Sciences’ sales representatives in reaching both physicians and health systems and will also actively participate in extending and deepening the Cologuard marketing campaign. Exact Sciences and Pfizer seek to increase colorectal cancer screening rates by accelerating adoption of Cologuard, a test that’s fully covered by Medicare and most major health insurance plans. Exact Sciences brings a sales force with expertise in colorectal cancer, the innovative science of Cologuard and a recognizable direct-to-consumer marketing campaign. Pfizer brings a large and experienced sales force and relationships integrating with the leading health systems, two areas where Cologuard is most often prescribed, along with deep marketing expertise. Under the terms of the agreement, Pfizer will co-promote Cologuard with Exact Sciences beginning in Q4. Exact Sciences will maintain responsibility for all aspects of manufacturing and laboratory operations of Cologuard. Pfizer will share gross profits and marketing expenses equally above an agreed upon baseline.

https://bit.ly/2OXv7tN